Peripheral arterial disease (PAD) results from narrowing of the peripheral arteries that supply oxygenated blood and nutrients to the legs and feet, This pathology causes symptoms such as intermittent claudication (pain with walking), painful ischemic ulcerations, or even limb-threatening gangrene. It is generally believed that the vascular endothelium, a monolayer of endothelial cells that invests the luminal surface of all blood and lymphatic vessels, plays a dominant role in vascular homeostasis and vascular regeneration. As a result, stem cell-based regeneration of the endothelium may be a promising approach for treating PAD.
1. The protocol for differentiating ESCs into endothelial cells is described elsewhere and is not the focus of this protocol 2, 3 . Briefly, the cells are allowed to differentiate, and the cells that are positive for the endothelial markers such as CD31 or vascular endothelial cadherin (VE-cadherin) are then purified by fluorescence activated cell sorting (FACS).
1. Bioluminescence can be used to track cells that are modified to express reporter genes such as firefly luciferase (fluc). For this application, our cells contain both fluc and enhanced green fluorescence protein (eGFP) fusion gene under the control of an internal ubiquitin promoter. In order to modify the cells, the transgene lentiviral vector containing key optimized genetic elements to fulfill bio-safety criteria as well as increased transduction efficiency, pFU-FG vector developed in our lab carrying the fluc-eGFP fusion reporter gene can be used to stably transduce the cells after differentiation. This fusion construct enables both bioluminescence and fluorescence tracking of the transplanted cells. The procedure for generating virus particles, transduction and production of labeled cells that express reporter genes is described elsewhere 4 .
1. Begin the procedure by preparing a mouse that has undergone hindlimb ischemia for cell transplantation. To do this, place the mouse into the anesthesia induction chamber containing 1-3% isoflurane in 100% oxygen at a flow rate of 1L/min. 2. Leave the mouse in the induction chamber until it is unresponsive to external stimuli. Then remove the animal from the induction chamber. 3. Then, place the animal in the supine position onto the operating table and connect it to a continuous flow of 1-3% isoflurane in 100% oxygen at a flow rate of 1L/min. 4. Wipe the skin of the hindlimb with three alternating betadine and alcohol scrubs. 5. Once the skin is cleaned, obtain one million ESC-derived endothelial cells in 30 μL of phosphate buffered saline (PBS). Load these cells into a 28 gauge needle. 6. When the cells are ready, gently lift and extend the hindlimb to better visualize the location of the gastrocnemius muscle. While the leg is extended, insert the needle through the skin into the underlying muscle. Take care not to approach the bone. Gently and slowly inject the 30 μL cell mixture into the gastrocnemius. For intramuscular injection, 30 μL is close to the limit of volume that can be injected. Therefore, 28-gauge insulin syringes are preferred because, in our experience, they eliminate the loss volume in syringe needles. 7. After the injection is complete, return the mouse to the recovery cage and monitor it continuously until awake. Allow the animal to recover for several hours and then proceed with the in vivo bioluminescence imaging of the transplanted cells.
1. The transplanted ESC-derived endothelials cells were modified to express both the fluc and the eGFP fusion gene under the control of an internal ubiquitin promoter. Therefore, bioluminescence can be used to track the cells within the ischemic hindlimb. 2. To begin this step, turn on the bioluminescence imaging system and Living Image acquisition software. Then initialize the acquisition system and specify the dimensions of the field of view. 3. Next, place black matte paper onto the imaging box to absorb background emission.
Representative Results
A representative bioluminescence image of transplanted cells in the left ischemic hindlimb is shown in Figure 1 . During acquisition of bioluminescence, the intensity will increase with time, and the maximum value obtained during the time course should be reported as the final value.
Discussion
ESCs are a promising cell source for the treatment of tissue ischemia because of their plasticity of differentiation and their ability to give rise to cell lineages comprising all three germ layers, including endothelial cells. To overcome the ethical concerns associated with ESCs, induced pluripotent stem cells (iPSCs) may be an alternative pluripotent stem cell source that overcomes the ethical concerns. Besides ESCs, adult stem cells such as endothelial progenitor cells (EPCs) and hematopoietic stem cells (HSCs) can also be used, but these cell types may have limited therapeutic effect in patients with PAD. Intramuscular delivery of cells is minimally invasive and easy to perform, and this mode of delivery is also amenable to the delivery of soluble factors or plasmids. However, for easier access of the transplanted cells to the vasculature, systemic delivery into the femoral artery or tail vein can be used instead of intramuscular injections.
